Lamictal (lamotrigine) is not an antidepressant. It is classified as an anticonvulsant, originally developed to treat seizures. However, it has a well-established role in treating the depressive side of bipolar disorder, which is likely why it comes up in conversations about depression. The distinction matters because its effectiveness depends heavily on which type of depression you’re dealing with.
What Lamictal Is Approved For
The FDA approves lamotrigine for two main purposes: epilepsy and bipolar I disorder. For epilepsy, it treats partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. For bipolar disorder, it is specifically approved as a maintenance treatment to delay the return of mood episodes, including depression, mania, and mixed episodes, in people who have already been treated for an acute episode.
That maintenance role is key. Lamictal isn’t approved to pull someone out of a depressive episode right now. It’s approved to keep depressive episodes from coming back once a person with bipolar I disorder has stabilized. Major clinical guidelines from CANMAT and ISBD list it as a first-line maintenance treatment for both bipolar I and bipolar II disorder, alongside lithium and quetiapine.
How It Works in the Brain
Lamotrigine’s mechanism isn’t fully understood, but it primarily blocks voltage-gated sodium channels on nerve cells. This stabilizes the cell membrane and reduces the release of glutamate, an excitatory brain chemical involved in both seizure activity and mood regulation. There is also evidence it interacts with calcium channels, which may broaden its effects on brain signaling. This is a fundamentally different mechanism from traditional antidepressants, which typically target serotonin, norepinephrine, or dopamine.
Bipolar Depression vs. Unipolar Depression
This is the most important distinction for anyone wondering whether Lamictal could help their depression. The evidence splits cleanly depending on diagnosis.
For bipolar depression, lamotrigine works. A large meta-analysis of randomized controlled trials found that lamotrigine monotherapy was superior to placebo for treating acute bipolar depressive episodes. As a maintenance treatment, it reduced the risk of depressive relapse by about 22% compared to placebo and significantly extended the time before another depressive episode returned. These findings are consistent enough that every major treatment guideline recommends it.
For unipolar depression (sometimes called major depressive disorder or “regular” depression), the picture is very different. When researchers pooled the data from multiple trials, including three that were never published, lamotrigine was no better than placebo as a standalone treatment. Adding it to an SSRI also showed no significant benefit for standard unipolar depression. In short, if you have depression without any history of manic or hypomanic episodes, lamotrigine is unlikely to help on its own.
The Exception: Treatment-Resistant Depression
There is one scenario where lamotrigine may have a role in unipolar depression. A meta-analysis of eight randomized trials involving 677 patients found that adding lamotrigine to an existing antidepressant improved depression scores and response rates in people whose depression had not responded to standard treatment. The benefit was more pronounced in patients with more severe and longer-lasting illness, and it worked better when added to SSRIs than to SNRIs. This use is entirely off-label, and the authors noted that the strongest positive results came from studies conducted in China, while non-Chinese trials did not reach statistical significance on their own. Still, it positions lamotrigine as one option clinicians may consider when first-line antidepressants have failed.
Why the Slow Start Matters
One thing that surprises many people prescribed lamotrigine is how slowly the dose increases. Unlike most antidepressants, which can be started at or near the target dose, lamotrigine requires a gradual titration over several weeks. This isn’t optional. The slow ramp-up is designed to minimize the risk of a serious skin reaction called Stevens-Johnson syndrome, a rare but potentially life-threatening condition where the skin and mucous membranes blister and peel. Across more than 18,000 patients in clinical trials, the incidence was about 0.04%, or roughly 1 in 2,500 people. Starting low and increasing slowly dramatically reduces this risk. If you develop any rash during the first few months, your prescriber will want to evaluate it immediately.
Oral Contraceptives and Blood Levels
Women taking combined oral contraceptives should be aware of a significant drug interaction. Estrogen-containing birth control pills reduce lamotrigine blood levels by more than 50%. In one study, women on oral contraceptives had average lamotrigine levels of 13 micromol/L compared to 28 micromol/L in women not taking them. This means lamotrigine may become less effective during the active pill weeks and then spike during the placebo week, potentially causing side effects or mood instability. Your prescriber may need to adjust the dose or discuss alternative contraception.
How Lamictal Compares to Antidepressants
Traditional antidepressants like SSRIs and SNRIs can be dangerous in bipolar disorder because they risk triggering manic episodes. This is precisely why lamotrigine fills such an important niche. It addresses the depressive pole of bipolar illness without the same risk of flipping someone into mania. For people with bipolar depression, it functions like an antidepressant in practical terms, even though it isn’t one by classification.
For people with straightforward unipolar depression, lamotrigine is not a substitute for proven antidepressants. It lacks the evidence base as a first-line or even second-line option for that condition. Its role there is limited to augmentation in treatment-resistant cases, and even that evidence is mixed.
The bottom line: lamotrigine treats depression, but only certain kinds. If your clinician prescribed it, the reason almost certainly relates to bipolar disorder or to depression that hasn’t responded to conventional treatments.